^
Association details:
| Biomarker: | FAT4 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer
Published date:
02/25/2022
Excerpt:
...the relationship between FAT1/2/3/4 mutations and efficacy of immunotherapy was explored in the Hellmann cohort consist of patients with NSCLC....In this cohort, FAT4 mutations were significantly associated with better BOR rate (Figure 7B, χ2 = 4.723, P = .029), but not PFS (Figure 7A, P > .05) and DCB rates (Figure 7C, P > .05).
DOI:
https://doi.org/10.1177/10732748221076682
